SCHEMBL1196958

SCHEMBL1196958

COc1ccc([N+](=O)[O-])c(CC#N)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 5/20 0.36
MAPK1 P28482 2/20 0.36
EGFR P00533 1/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32669218 1.00 ALDH1A1 (0.42) ALDH1A1HPGDTDP1LMNAL3MBTL1
SCHEMBL31275717 0.83 ALDH1A1 (0.42) ALDH1A1HPGDTDP1LMNAL3MBTL1
SCHEMBL34472127 0.81 ALDH1A1 (0.45) ALDH1A1TDP1LMNAL3MBTL1MAPT
SCHEMBL942641 0.79 ALDH1A1 (0.56) ALDH1A1HPGDTDP1LMNAL3MBTL1
SCHEMBL31143078 0.79 ALDH1A1 (0.56) ALDH1A1HPGDTDP1LMNAL3MBTL1
SCHEMBL1401678 0.79 SGMS2 (0.46) ALDH1A1HPGDLMNAMAPTMEN1
SCHEMBL27538825 0.78 ALDH1A1 (0.45) ALDH1A1HPGDTDP1LMNAMAPT
SCHEMBL297502 0.77 SMN1; SMN2 (0.43) ALDH1A1TDP1LMNAL3MBTL1GAA
SCHEMBL10258689 0.77 ALDH1A1 (0.45) ALDH1A1TDP1LMNAL3MBTL1MAPT
SCHEMBL3028315 0.77 TUBB1 (0.38) ALDH1A1MAPTTUBB1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-02-05 US disclosed
EP-3862354-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2021-08-11 EP disclosed
EP-2824105-B1 Indolopyridines as Eg5 kinesin modulators 4SC AG (DE) 2021-03-31 EP disclosed
EP-2824105-A1 Indolopyridines as Eg5 kinesin modulators 4SC AG (DE) 2015-01-14 EP disclosed
US-8530493-B2 Indolopyridines as Eg5 kinesin modulators 4SC AG (DE) 2013-09-10 US disclosed
US-20110027226-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) 4SC AG (DE) 2011-02-03 US disclosed
EP-2178875-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 ) 4SC AG (DE) 2010-04-28 EP disclosed
US-20090246169-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS NYCOMED GMBH (DE) 2009-10-01 US disclosed
US-20090233902-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2009-09-17 US disclosed
EP-2033962-A1 Tetracyclic indolopyridines as EG5 inhibitors 4SC AG (DE) 2009-03-11 EP disclosed
WO-2009024190-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 ) 4SC AG (DE) 2009-02-26 WO disclosed
WO-2009024613-A1 TETRACYCLIC INDOLOPYRIDINES AS EG5 INHIBITORS 4SC AG (DE) 2009-02-26 WO disclosed
EP-1996592-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS Nycomed GmbH (DE) 2008-12-03 EP disclosed
EP-1994033-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2008-11-26 EP disclosed
WO-2007096393-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2007-08-30 WO disclosed
WO-2007096395-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS HTR4, OPRM1, HTR7 ALDH1A1 858/4885HPGD 1968/4885TDP1 1453/4885
US-20110027226-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) KIF5A, KIF5C, KIF5B ALDH1A1 3349/4885HPGD 4187/4885TDP1 457/4885
US-20090233902-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS KIF5A, KIF5C, KIF5B ALDH1A1 2483/4885HPGD 3444/4885TDP1 503/4885
US-20090246169-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS KIF5A, KIF5C, KIF5B ALDH1A1 2483/4885HPGD 3444/4885TDP1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.